Order Article Reprints

Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles TL, et al. Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. Current Oncology. 2025; 32(3):144. https://doi.org/10.3390/curroncol32030144

Williamson, Julie, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Debra Jamison, Dan Sageser, Joanne Jeter, Tawnya L. Bowles, and et al. 2025. "Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma" Current Oncology 32, no. 3: 144. https://doi.org/10.3390/curroncol32030144

Williamson, J., Fadlullah, M. Z. H., Kovacsovics-Bankowski, M., Gibson, B., Swami, U., Erickson-Wayman, A., Jamison, D., Sageser, D., Jeter, J., Bowles, T. L., Cannon, D. M., Haaland, B., Schroeder, J. D., Nix, D. A., Atkinson, A., Hyngstrom, J., McPherson, J., Tan, A.-C., & Hu-Lieskovan, S. (2025). Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma. Current Oncology, 32(3), 144. https://doi.org/10.3390/curroncol32030144